The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
The $180 million offering is well above the firm's initial target for proceeds of $100 million.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
Revenues for the quarter dropped about 55 percent compared to revenues for the same quarter in 2014.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
The IPO could bring in $51.4 million in net proceeds for the molecular diagnostics firm.
The microbial genetics analysis firm went public today offering 2.85 million units for $17.1 million in gross proceeds.
The firm expects to receive net proceeds of up to $51.4 million at a price range of $13 to $15 per share for its IPO.
The company issued more than 8.6 million shares at €11.50 per share in its IPO. Its shares list on Euronext Brussels under ticker symbol "BCART."
The microbial genetics analysis firm said in an SEC document that it plans to offer between 2.5 million units of stock and warrants at between $5.50 and $6.50 per unit.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.